Regina Prindle, NP
Psychiatric/Mental Health · Coeur D Alene, IDNPI 1104896075
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.1% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 25.2% of the total. Reporting peaked in 2023 at $559 and has fallen 65.2% since, to $194 in 2025.
Across 103 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$462
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$199
- Johnson & Johnson$188
- Sunovion Pharmaceuticals Inc.$172
- Otsuka America Pharmaceutical, Inc.$151
- Lundbeck LLC$145
- plus $520 from 10 others
What the payments were for
- Food & beverage$1,69192%
- Education$1458%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 17 | $462 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $199 |
| Johnson & Johnson | 11 | $188 |
| Sunovion Pharmaceuticals Inc. | 14 | $172 |
| Otsuka America Pharmaceutical, Inc. | 7 | $151 |
| Lundbeck LLC | 8 | $145 |
| AbbVie | 7 | $107 |
| Neurocrine Biosciences, Inc. | 6 | $105 |
| Alkermes, Inc. | 6 | $105 |
| Corium, LLC | 4 | $50 |
| E.r. Squibb & Sons, L.L.C. | 2 | $42 |
| Indivior Inc. | 2 | $40 |
| Sage Therapeutics, LLC | 1 | $27 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Eisai Inc. | 1 | $14 |
| Merck | 1 | $13 |
How this compares
$1,836 in reported general payments places this provider in the 75th percentile of 221 psychiatric/mental health providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 96 | $309,629 |
| Invega TrinzaPaliperidone Palmitate | 26 | $234,326 |
| VraylarCariprazine Hcl | 121 | $169,943 |
| IngrezzaValbenazine Tosylate | 12 | $95,130 |
| Abilify MaintenaAripiprazole | 29 | $78,115 |
| RexultiBrexpiprazole | 41 | $59,692 |
| Lurasidone Hcl | 169 | $49,897 |
| CaplytaLumateperone Tosylate | 26 | $44,543 |
| AuvelityDextromethorphan Hbr/Bupropion | 34 | $36,964 |
| Risperdal ConstaRisperidone Microspheres | 15 | $34,514 |
| Aripiprazole | 254 | $34,464 |
| Clozapine | 186 | $24,247 |
| TrintellixVortioxetine Hydrobromide | 23 | $10,739 |
| Clomipramine Hcl | 57 | $10,474 |
| Olanzapine | 268 | $9,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $188 | $578,469137 claims |
| AbbVieVraylar | $107 | $169,943121 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $151 | $137,80770 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $105 | $95,13012 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $199 | $44,54326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 221 psychiatric/mental health providers in Idaho.
Other psychiatric/mental health in Coeur D Alene
- Jared PetrickCoeur D Alene$32K
- Peter GourleyCoeur D Alene$5K
- Robert LeethCoeur D Alene$4K
- Zachary HarmanCoeur D Alene$2K
- Janet GourleyCoeur D Alene$2K
- Jason MartinIdaho Falls$78K
- Misti NewsonBoise$56K
- Carey CrillBoise$19K
- Deborah RushMeridian$13K
- Ashley CroftCaldwell$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.